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Abstract
Over the past 20 years, investigators world-wide have developed and utilized dobutamine magnetic resonance
stress testing procedures for the purpose of identifying ischemia, viability, and cardiac prognosis. This article traces
these developments and reviews the data utilized to substantiate this relatively new noninvasive imaging
procedure.
Introduction
The identification of myocardial ischemia and viability is
critical to the management of patients with coronary
artery disease (CAD), and as such, over the last 20
years, dobutamine stress cardiovascular magnetic reso-
nance (CMR) has been developed for the purpose of
identifying these conditions. Today, dobutamine CMR
incorporates assessments of left ventricular (LV) wall
motion, myocardial perfusion, and tissue characteriza-
tion. These data are useful for diagnosing and forecast-
ing prognosis in individuals with CAD. In this article,
we review the performance of dobutamine stress CMR
and describe the clinical utility of this technique for
managing patients with known or suspected CAD. In
addition, recent innovations are described that may
extend principles learned from dobutamine stress CMR
into exercise stress CMR.
Pharmacological effects of Dobutamine and
Atropine
Dobutamine is a synthetic, primarily b1-adrenergic,
catecholamine with mild a1- and b2-receptor agonist
activity [1,2]. At low doses (≤ 10 μg/kg/min), dobuta-
mine augments myocardial contractility and promotes
coronary vasodilation [3]; at higher doses (20-40 μg/kg/
min), it causes systematic vasodilation and serves as a
positive chronotrope. These later effects increase heart
rate and raise myocardial oxygen consumption by
increasing myocardial work [4]. Dobutamine can be
used during pharmacologic stress testing to identify
inducible ischemia due to flow limiting epicardial coron-
ary artery stenosis (Figure 1). Visually, this results in a
LV perfusion or wall motion abnormality (WMA).
Since dobutamine increases myocardial oxygen
demand, it is advantageous in patients who may need a
cardiac stress test but cannot exercise due to peripheral
vascular disease, physical incapacitation, or chronic
deconditioning [5]. To identify myocardial ischemia dur-
ing dobutamine stress CMR, it is important to achieve >
85% of the patient’s maximum predicted heart rate
response (MPHRR) for age during the exam. At this
“target” heart rate response, the sensitivity for identify-
ing inducible ischemia using this form of testing
increases [6]. To this end, often in conjunction with
dobutamine, atropine, a natural alkaloid of “atropa bella-
donna” and a competitive antagonist of muscarinic cho-
linergic receptors, is implemented to increase the heart
rate by inhibiting the vagal tone.
Safety Profile for Dobutamine/Atropine Stress
Multiple large studies have examined the safety profile
of dobutamine/atropine stress, dobutamine stress echo-
cardiography (DSE) [7-9], and CMR [10-12]. These stu-
dies were classified as having major or minor
complications. Major complications included severe
symptomatic hypotension, acute myocardial infarction
(MI), sustained ventricular tachycardia, ventricular fibril-
lation, rupture of the free wall of the left ventricle or LV
septal defect, transient ischemic attack, and death.
Minor complications included anxiety, nausea, and atro-
pine poisoning with hallucinations lasting several hours
in the absence of myocardial ischemia and hypotension.
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events with DSE have been reported in the range of 1
per 2000 to 5 per 1000 [7-9]. Overall, data suggest the
rates of major adverse events during DCMR are similar
(approximately 1 per 1000) to the rates observed during
DSE [10-12]. (Table 1).
Although serious complications are not common, spe-
cial safety measures are required when performing CMR
stress tests. Recommendations for procedures and facil-
ities to perform stress have been previously published
[10-14]. Physicians and health-care providers should
recognize the importance of identifying ischemia
promptly, as major events are usually associated with
the continued administration of pharmacological stress
in the setting of myocardial ischemia.
CMR Protocol
Interpretation of LV myocardial perfusion or wall
motion is performed during dobutamine/atropine phar-
macologic infusions to identify myocardial ischemia and
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Figure 1 Sequence of events after coronary artery occlusion. Ischemic cascade represents the sequence of pathophysiological events
following disruption of coronary artery blood flow.
Table 1 Major and Minor Complications of Dobutamine-Atropine Stress
Study Modality Number of Patients Minor events Major events Deaths
Rodríguez García et al (7) DSE + A 325 57% 21% 1
Picano et al (8) DSE + A 2799 78% 5% 0
Geleijnse et al (9) DSE + A 2246 71% 5% 0
Wahl et al (10) DCMR + A (54%) 1000 64% 6% 0
Kuijpers et al (11) DCMR 400 71% 3% 0
Hamilton et al (12) DCMR + A (27%) 469 67% 0 0
A = atropine, DCMR = dobutamine cardiovascular magnetic resonance, DSE = dobutamine stress echocardiography
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Page 2 of 16viability. To this end, when assessing LV wall motion, a
17-segment model defined by the American Heart Asso-
ciation (AHA) and American College of Cardiology
(ACC) is used in which each segment is scored as: 1 =
normal, 2 = hypokinetic, 3 = akinetic, and 4 = dyski-
netic. Ischemia is defined as ≥ 1 segments showing
inducible WMAs (i.e. an increase in LV wall motion
score ≥ 1 during testing; in addition, a biphasic response
is considered to indicate ischemia) [15,16]. Once ische-
mia is detected, tests are terminated; other reasons to
terminate testing include symptomatic hypo- or hyper-
tension, marked ventricular arrhythmia, or unexpected
neurological findings [10-12,14].
Cardiovascular magnetic resonance imaging is well
suited for visualizing LV wall motion during dobutamine
stress. With CMR, one can visualize the LV myocardium
in multiple tomographic planes [17-19]. The image
acquisition can be standardized, thus limiting reliance
on the technique of an individual technologist for
acquiring high-quality images [20,21]. Dobutamine stress
CMR tests are usually performed on short, 1.5 Tesla (T),
closed-bore systems, with bore diameters ranging from
55-70 cm (Table 2).
The performance of dobutamine stress testing with
CMR is straightforward. Once contraindications to
CMR scanning are confirmed (Table 3), a 12-lead elec-
trocardiogram (ECG) is performed outside of the mag-
net. Then, after establishing intravenous access, the
patient is positioned supine on the MR scanning table.
Attached to the patient is a phase array surface coil,
ECG monitoring leads, respiratory gaiting belt, pulse
oximetry monitor, and brachial blood pressure cuff [22].
A registered nurse (to administer medications and
record rhythms) and physician continuously monitor the
heart rate and rhythm, blood pressure, oxygen satura-
tion, and respiratory rate throughout the study [14,22].
At baseline in dobutamine stress CMR, cine white
blood images are obtained in three apical views: 2, 3, and
4-chamber views (Figures 2 and 3), and in at least three
short-axis planes (the base, middle portion and apex). In
situations where LV volumes are to be acquired, it is
recommended to also acquire short-axis slices (spanning
from the LV base to the apex) in order to calculate LV
volumes using a Simpson’s rule technique [23].
Images are acquired during five-minute dobutamine
infusions of 7.5 mcg/kg/min, followed by 20-50 μg ￿ kg
-1
￿ min
-1 designed to achieve 85% of the MPHRR for age.
If 85% MPHRR is not achieved during obutamine stress
CMR, atropine is administered in 0.1 to 0.3-mg incre-
ments to augment the heart-rate response. At each stress
level, 3 cine short- and 3 cine- long-axis images of the
LV are acquired and images are compared side by side
with baseline images for assessment of the development
of regional wall motion abnormalities, which indicate
stress induced ischemia. Criteria for terminating pharma-
cologic stress are shown in Table 4. At the completion of
the study, additional images are obtained to confirm that
LV wall motion has returned to baseline.
CMR techniques for dobutamine stress CMR
From 1990-96, spoiled gradient-echo imaging techniques
were used to identify LV regional WMA induction of
ischemia during dobutamine stress CMR [24]. However,
in the setting of impaired global or regional LV systolic
function that promotes slow intracavitary flow, steady-
state free precession (SSFP) imaging has been utilized.
This type of imaging sequence yields a higher blood
pool signal intensity and thus a very high contrast to
Table 2 Utility of dobutamine wall motion stress CMR for identifying ≥ 50% coronary arterial luminal narrowing
Author [Ref#] Patients
(n)
Men
(%)
Mean age
(years)
Dobutamine
dose
(μg/kg/min)
Sensitivity
(%)
Specificity
(%)
Gebker R et al.[47] 455 65 64 40+atropine 91 70
Hundley et al.[41] 163 56 NS 40+atropine 83 83
Korosglou et al.[32] 1493 74 65 40+atropine 89 94
Kuijpers et al.[31] 194 67 62 40 96 95
Nagel et al.[40] 208 71 60 40+atropine 86 86
Paetsch et al.[27] 79 66 61 40+atropine 89 80
Paetsch et al.[45] 150 83 61 40+atropine 78 88
Pennell et al.[24] 25 74 52 20 91 100
Schalla et al.[28] 22 80 60 40+atropine 81 83
Van Rugge et al.[38] 45 82 61 20 81 100
Van Rugge et al.[39] 39 86 60 20 91 80
Wahl et al.[42] 160 - 59 40+atropine 89 84
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Page 3 of 16noise ratio between intracavitary blood and the myocar-
dium. In combination with parallel image acquisitions
(SENSE, sensitivity encoding), one may acquire up to 50
phases/cardiac cycle during an end-expiratory
breathhold of about 6 seconds at heart rates of 190-220
bpm [25-27]. The in-plane spatial resolution of SSFP
cine scans usually lies in the range of 1.6 mm × 1.6 mm
with a slice thickness of 8 mm.
Table 3 Contraindication for dobutamine/atropine stress CMR
Dobutamine ￿ Severe arterial hypertension (≥ 220/120 mmHg)
￿ Unstable angina pectoris
￿ Significant aortic stenosis (aortic valve gradient > 50 mmHg or aortic valve area < 1 cm2)
￿ Complex cardiac arrhythmias including uncontrolled atrial fibrillation
￿ Hypertrophic obstructive cardiomyopathy
￿ Myocarditis, endocarditis, pericarditis
￿ Uncontrolled congestive heart failure
￿ Previous manifestations of hypersensitivity to dobutamine
Atropine ￿ Narrow angle glaucoma, myasthenia gravis, obstructive uropathy, obstructive gastrointestinal disorders
CMR- examination ￿ Non compatible biometallic implants and pacemaker or implanted defibrillators (ICDs)
￿ Claustrophobia
Figure 2 (Panel A): Myocardial segmentation during dobutamine stress CMR. Panel A: Strategy for obtaining 3 apical (3-chamber, 4-
chamber, and 2-chamber) and 3 short-axis (basal, middle, and apical) cardiovascular magnetic resonance views of the left ventricle. On each
image the myocardium is gray and the blood pool white. The white solid line on the coronal locator, and the white dotted lines on the 3-
chamber view and basal short-axis view indicate the slice positions for obtaining the subsequent views demarcated by the white arrows.
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cardiac functional studies without ECG triggering or
breath-holding have been implemented during dobuta-
mine stress CMR in patients with cardiac arrhythmia
(frequent ectopic ventricular beats and atrial fibrillation)
and those incapable of breath holding. Schalla, et al [28]
have demonstrated the feasibility and accuracy of real-
time MR imaging under stress conditions, however,
both the spatial and temporal resolutions were reduced
compared with the standard breath-hold SSFP approach.
New sequences with parallel imaging in the time
domain, such as k-t BLAST (broad-use linear acquisition
speed-up technique) and k-t SENSE [29,30] may even-
tually lead to further improvement in real-time imaging
(Table 5).
Myocardial tissue tagging has been utilized in two
fashions during dobutamine stress CMR to enhance the
sensitivity of wall motion results for identifying ischemia
due to flow limiting epicardial coronary artery stenoses.
In the first, Kuijpers, et al. [31] demonstrated the utility
of tissue tagging to enhance qualitative identification of
LV WMA indicative of ischemia. In the second, quanti-
tative methods have proven useful to identify abnormal-
ities of myocardial strain. In fact, tagged CMR images
have been used to quantify LV wall motion in systole
and diastole to detect early evidence of ischemia during
low dose dobutamine infusions. Such an imaging
approach may prove useful in limiting the duration (and
Figure 3 (Panel B): Myocardial segmentation during dobutamine stress CMR. Panel B: White lines demarcate the apical (AP), middle (Mid),
and basal (Bs) segments of the anteroseptal (AS), anterior (Ant), lateral (Lat), posterior (Post), and inferior (Inf) walls.
Table 4 Criteria for stopping dobutamine infusion
Criteria
1 Target heart rate achieved
2 Intractable symptoms: severe angina pectoris, severe dyspnea
3 New or worsening WMA in ≥ 1 LV segment
4 Drop in systolic blood pressure of ≥ 40 mmHg with change in
reported symptoms
5 Blood pressure increase greater than 240/120 mmHg
6 Complex cardiac arrhythmias
7 Patient request
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Page 5 of 16potential adverse eventws) of high dose dobutamine
stress CMR [32]. In addition, Paetsch, et al.[ 3 3 ]h a s
recently reported that diastolic parameters (time to peak
untwist) derived from myocardial tagging could identify
patients with significant coronary artery stenosis at the
level of low-dose dobutamine stress. Importantly how-
ever, studies with larger participant numbers as well as
reliable quantitative software are needed before these
early preliminary results can be adopted clinically [34].
While the majority of dobutamine stress CMR has
been performed at 1.5T, studies on 3.0 Tesla systems
have been attempted [35]. Current SSFP cine sequences
at 3.0 Tesla suffer from susceptibility artifacts/magnetic
field inhomogeneities rendering endocardial border
recognition difficult particularly during the high flow
states encountered at high levels of intravenous dobuta-
mine and atropine. New multitransmit technology may
overcome these limitations in the near future [36].
Clinical applications - Identification of inducible
ischemia
Pennell, et al.[ 2 4 ]r e p o r t e dt h ef i r s tu s eo fL Vw a l l
motion analyses during dobutamine stress CMR in 25
patients with exertional chest pain. Results from dobuta-
mine stress CMR were compared with thallium-201 sin-
gle photon emission tomography (SPECT) and contrast
coronary angiography (Figure 4). The subjects received
dobutamine infusions of up to 20 μg/kg/min and under-
went conventional gradient-echo cine dobutamine stress
CMR. The sensitivity of dobutamine stress induced LV
wall motion abnormalities for detecting SPECT evidence
of ischemia was 91%, and there was 90% agreement
between SPECT and dobutamine stress CMR for identi-
fying results indicative of ischemia. Twenty-one (96%) of
these patients had reversible myocardial ischemia shown
by dobutamine thallium tomography, and 20 (91%) had
reversible WMAs shown by dobutamine stress CMR.
Other early studies confirmed these results by demon-
strating the overall sensitivities of 81-84% for detecting
coronary arterial luminal narrowings ≥ 50% [37-39].
Limitations of these early studies include the fact that
they were relatively small participant numbers (20-60
patients per study), were performed in single centers,
and enrolled participants with known CAD prior to
stress testing. Also, LV wall motion was analyzed at
baseline and compared with peak stress; it was not
visualized continuously throughout testing. As a result,
the tests were terminated prematurely when patients
developed chest pain. Thus, while these studies high-
lighted the feasibility of dobutamine administration in
the CMR environment, the clinical utility of dobutamine
stress CMR remained in question.
Two larger prospective studies in the late 1990’s estab-
lished the clinical utility of dobutamine stress CMR. In
the first, Nagel, et al. [40] compared the results of dobu-
tamine stress CMR with DSE in 208 subjects who
underwent both procedures for detection of significant
CAD, defined as > 50% coronary arterial luminal dia-
meter stenosis. Dobutamine was infused intravenously
up to 40 μg/kg/min in order to achieve ≥ 85% of the
MPHRR for age. Dobutamine stress CMR demonstrated
superior sensitivity (86% vs 74%), specificity (86% vs
70%), and diagnostic accuracy (86% vs 70%) in compari-
son with DSE (p < 0.05 for all). These differences were
most pronounced in patients with suboptimal acoustic
windows.
In the second study, Hundley, et al. [41] performed
complimentary work in 153 patients with a non-diag-
nostic DSE despite the use of second harmonic imaging.
When compared with contrast coronary angiography,
the sensitivity and specificity of dobutamine stress CMR
were both 83% for detecting coronary arterial luminal
narrowings of ≥ 50% by contrast coronary angiography
(Figure 5). After these studies confirming clinical utility
by Nagel, et al., and Hundley et al., Paetsch, et al., [27]
compared the diagnostic value of dobutamine stress MR
wall motion analyses with adenosine stress MR wall
motion and perfusion analyses in the same study partici-
pants during a single session examination. They found
dobutamine induced LV wall motion abnormalities
accurate and more sensitive and specific for identifying
inducible ischemia compared to perfusion assessments
alone. An important limitation of this work was the
absence of delayed enhancement methods to identify
infarcts involving the LV myocardium.
Detection of new or worsening WMAs in the sub-
group of CAD patients with resting WMAs is known to
be especially difficult. However, Wahl et al.[ 4 2 ]
Table 5 Advantages and Disadvantages of White Blood Cine Imaging Techniques
Technique Advantage Disadvantage
FGRE (breathhold) Reliable at elevated regular heart rate Breathhold = 12 seconds
FGRE (respiration-triggered) No Breath-holding 45-second scan
SSFP Apical views Artifact at elevated heart rates
SENSE Rapid acquisition Unknown reliability; potentially low temporal resolution
Real-time Rapid acquisition Noise, lower spatial and temporal resolution
Abbreviations: FGRE = fast gradient-echo, SSFP = steady-state free precession, SENSE = sensitivity encoding.
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CMR in 160 consecutive patients with pre-existing
WMAs who had sustained prior MI and/or prior coron-
ary arterial revascularization. The sensitivity and specifi-
city for detecting coronary arterial luminal narrowing of
≥ 50% were 89% and 84%, respectively. Additionally, the
overall sensitivity for detection of significant CAD in
patients with single-, double-, and triple-vessel disease
was 87%, 91%, and 100%, respectively. This study
demonstrated that high dose dobutamine stress CMR
c a nb eu s e f u le v e ni np a t i e n t sw i t hp r e e x i s t i n gW M A s
and history of coronary revascularization. As shown in
Table 2, a recent meta-analysis revealed a sensitivity of
0.83 (95% confidence interval 0.79 to 0.88) and specifi-
city of 0.86 (95% confidence interval 0.81 to 0.91) of
high dose dobutamine stress CMR for identifying > 50%
coronary arterial luminal narrowings in patients with a
relatively high disease preval e n c e( d i s e a s ep r e v a l e n c e=
70.5%) [43].
Beside its consistently high diagnostic accuracy, dobuta-
mine stress CMR has been reported to provide a low
interobserver variability (kappa = 0.81), and a high repro-
ducibility (p = 0.91). [43] In the setting of multiple obser-
vers from different institutions performing a diagnostic
reading of dobutamine stress CMR examinations acquired
from a single center, the interobserver variability was low
for identifying inducible LV WMAs indicative of coronary
arterial luminal narrowings ≥ 50% [44,45].
As imaging technology has advanced, it is now possi-
ble to examine myocardial perfusion in addition to wall
motion during dobutamine stress. In 2008, Lubbers,
et al. [46] and Gebker, et al. [47] were the first to assess
the additional value of first pass myocardial perfusion
imaging during peak dose of dobutamine stress CMR
for the detection of myocardial ischemia. The addition
of first-pass myocardial perfusion imaging to wall
motion assessments during peak-dose dobutamine stress
CMR improved sensitivity for the diagnosis of coronary
artery disease. Gebker, et al., identified that the accuracy
of dobutamine stress CMR-wall motion was influenced
by LV geometry: in patients with concentric remodeling
or hypertrophy, additional first-pass perfusion imaging
during high dose dobutamine stress improved the diag-
nostic accuracy for the detection of CAD [48].
Several small studies have reported on the effectiveness
of exercise as a mechanism to induce LV WMA indicative
of ischemia. Exercise testing offers important additional
information such as exercise capacity, blood pressure
response, development of arrhythmias, and the presence
of symptoms (e.g. chest pain) during exercise [49]. Jekic, et
al. examined 20 healthy subjects using a treadmill exercise
CMR protocol and found that all left ventricular segments
Figure 4 Timeline displaying the progression of dobutamine stress CMR research over the past 20 years.E a c hb o xr e p r e s e n t sa
published manuscript of peer reviewed original research with the first author, a short summary, and the sample size (n) within the study.
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addition, Rerkpattanapipat, et al., demonstrated a 79% sen-
sitivity of maximal exercise treadmill MRI for identifying ≥
50% coronary arterial luminal narrowings in patients with
primarily single vessel CAD [50].
Prognostic value of DCMR stress
Several studies, including those involving > 1000 patients,
have provided insight into subgroups of patients where
dobutamine stress CMR assessment of ischemia may
forecast cardiac prognosis. In 2002, Hundley, et al. [51]
evaluated 279 patients who underwent dobutamine stress
CMR followed for an average of 20 months. In a multi-
variable analysis, the presence of ischemia or an LVEF <
40% were associated with future MI and cardiac death,
independent of the presence of risk factors for coronary
arteriosclerosis or MI. In a subsequent study of these
same participants, inducible ischemia involving the LV
Figure 5 Inducible left ventricular wall motion abnormalities indicative of ischemia. A resting end-systolic frame from a 2-chamber view is
shown in the top left corner demonstrating normal left ventricular contraction with no wall motion abnormalities. The top right image shows a
peak dobutamine end-systolic cine view; the yellow arrow highlights hypokinesis of the inferoapical region. The bottom images are a caudal
view of the right anterior oblique projection during contrast coronary angiography. The bottom left image exhibits a 70% proximal left anterior
descending, 80% obtuse marginal, and 60% distal circumflex lesions. The red arrow in the bottom right highlights an 80% lesion in the mid-right
coronary artery.
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diac death (independent of the location of the myocardial
segment within the apex); ischemia isolated to basal and
middle segments was not [52].
Subsequent to these studies, Kuijpers, et al., [53] fol-
lowed 214 patients with a negative dobutamine stress
CMR study with an average of 24 months. Dobutamine-
CMR showed a positive and negative predictive value of
95% and 93%, respectively, for identifying major adverse
cardiac events. In participants without evidence of ische-
mia the reported cardiovascular event-free survival rate
was 96.2%.
In comparison with adenosine stress CMR, results
from dobutamine stress CMR have similar prognostic
accuracy. In a larger patient population undergoing
combined dobutamine stress CMR and adenosine first-
pass perfusion MR imaging, Jahnke, et al., demonstrated
similar 2- year event-free survival rates for both stres-
sors [54]. Most importantly, these authors identified a 2-
year relatively event-free period of cardiac events when
stress CMR tests were negative. In the future, dobuta-
mine stress CMR results may be useful to accomplish
decisions regarding clinical care [54].
CMR also has been utilized to determine preoperative
cardiovascular risk in patients undergoing non-cardiac
surgery. In the subgroup of patients with intermediate
clinical predictors of future cardiac events, a positive
dobutamine stress CMR test proved to be an indepen-
dent factor for predicting MI, cardiac death or conges-
tive heart failure during or after the surgery [50].
Dobutamine stress CMR in Women
The diagnosis of CAD in women presents challenges
not seen in testing men [55,56]. Differences in the epi-
demiology of CAD between men and women render
women at generally lower risk than their male counter-
parts until the seventh decade of life. The high preva-
lence of nonobstructive CAD and single-vessel disease
in women generally results in decreased diagnostic accu-
racy and higher false-positive rate for noninvasive test-
ing in women versus men [55,56]. The substantial under
representation of women in studies of noninvasive test-
ing further limits the evidence-based information on
which to base clinical decision making [57].
To this end, Gebker, et al., [58] performed a compara-
tive study to assess the diagnostic value of dobutamine
stress CMR for the detection of CAD in men and
women. They reported that the diagnostic value for
identifying myocardial ischemia indicative of coronary
arterial luminal narrowings of > 70% was similar for
men (sensitivity, specificity, accuracy; 86%, 83%, 85%)
and women (85%, 86%, 85%, respectively).
Wallace, et al. [59] recently determined the utility of
dobutamine stress CMR results for predicting cardiac
prognosis in women. Two hundred sixty-six consecu-
tively referred women who underwent dobutamine
stress CMR were followed up to an average of 6.2 years
after dobutamine stress CMR. Similar to men, dobuta-
mine stress CMR results were found efficacious for
identifying women at risk for future MI or cardiac
death. In women with known or suspected ischemic
heart disease, dobutamine stress CMR results were inde-
pendent predictors of cardiac events after accounting for
known risk factors for CAD and MI.
Limitations of dobutamine stress CMR wall
motion analyses
Several studies have identified patient populations in
which wall motion assessed during dobutamine stress
CMR may be insufficient for identifying those at risk for
CV events. The first such situation involves dobutamine
stress CMR in patients with a severe reduction in LVEF.
Dall’Armellina, et al.[ 6 0 ]d e m o n s t r a t e dt h a ti ni n d i v i -
duals with moderate to severe reductions in LVEF
(LVEF < 40%), a dobutamine-induced increase in wall
motion score index (a marker of inducible ischemia)
was not predictive of future MI and cardiac death
beyond the assessment of resting LVEF.
Increased LV wall thickness or left ventricular hyper-
trophy (LVH) appear to offer prognostic implications
independent of the presence of dobutamine induced LV
WMA. Recently, Walsh and colleagues [61] identified
that increased LV end-diastolic wall thickness in the
base of the septum or lateral wall was associated with
MI and cardiac death in individuals with a resting LVEF
> 55% and no inducible LV WMA indicative of ischemia
after dobutamine infused to achieve 85% of the MPHRR
for age. In a second study, Charoenpanichkit, et al.[ 6 2 ]
found that LVH was an independent prognostic marker
above and beyond assessments of LV WMA. In fact, in
those with LVH but without dobutamine induced
WMA, the future risk of MI and cardiac death was
found similar to those with a preserved LVEF and the
presence of LV WMA.
In one of the largest reported dobutamine stress stu-
dies worldwide, Korosoglou, et al. [63] reported the out-
comes of 1493 patients undergoing dobutamine stress.
Overall, patients’ prognosis and diagnostic accuracy
were similar to those observed in prior studies with
smaller numbers of participants. In this relatively large,
single-center study, dobutamine-induced LV wall
motion and perfusion abnormalities predicted future
adverse CV events after accounting for established risk
factors of CV disease.
The relatively large number of study participants also
allowed the investigators to reach important conclusions
regarding patient subgroups and associated comorbid-
ities. Important conclusions drawn from this study
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wall motion abnormalities forecasted CV prognosis in
those with or without myocardial perfusion deficits. The
converse, however, was not true, as perfusion assess-
ments only provided incremental prognosis information
in individuals who did not experience an inducible wall
motion abnormality during intravenous dobutamine.
Moreover, the prognostic utility of these additional per-
fusion images occurred only in those with existing LV
wall motion abnormalities at rest, those with known
coronary disease, or those with LV hypertrophy.
Second, the presence of dobutamine-induced LV wall
motion abnormalities forecasted cardiac prognosis in
individuals regardless of the pretest probability of coron-
ary artery disease (low, intermediate, or high). The
absence of inducible LV wall motion abnormalities only
conferred a favorable CV prognosis in those who were
at low or intermediate risk.
Finally, the results (positive or negative for ischemia)
of either wall motion or perfusion stress tests did not
add incremental information regarding CV prognosis in
individuals with a severely reduced LV ejection fraction
at rest (Figure 6). The results of this large study suggest
one should consider stress CMR imaging strategies
according to patient co-morbidities on an individualized
basis. In some individuals wall motion analyses may be
sufficient; whereas in others, wall motion may need sup-
plementation with perfusion imaging.
Dobutamine stress CMR for detection of
myocardial viability
Commonly, clinically important viable myocardium is
d e f i n e da st i s s u et h a tr e t a i ns contractile capability 6
weeks to 6 months following a successful coronary arter-
ial revascularization procedure. While several CMR ima-
ging and spectroscopic methods exist to identify
myocardial viability, 3 are used in the clinical setting:
measurement of resting LV end-diastolic wall thickness,
usual interpretation or quantitation of LV systolic or dia-
stolic performance during low dose (5 to 10 mcg/kg/min)
dobutamine stress CMR or quantitation of non viable
scarred or infracted myocardial tissue using late gadoli-
nium enhancement imaging. In this latter situation, as
would be expected, an inverse relationship exists between
the amount of scarred tissue and the chance a myocardial
segment will recover systolic thickening after successful
coronary arterial revascularization. For purposes of this
review, presented material will focus primarily on the
association between dobutamine induced changes in LV
performance and future resting LV performance after
successful coronary artery revascularization.
The first report of using low dose dobutamine infu-
sions to identify myocardial segments in patients with
coronary arteriosclerosis that would respond to coronary
artery revascularization was by Cigaroa, et al., in 1990
using DSE [64]. In this study, an improvement in LV wall
motion score index [WMSI] (an assessment of segmental
wall motion/the number of LV myocardial segments
assessed) during dobutamine predicted LV WMSI after
coronary artery revascularization. Since LV wall motion
can be difficult to assess in individuals with poor quality
transthoracic echocardiograms, other investigators have
sought to determine the utility of CMR for identifying
contractile reserve indicative of future recovery of func-
tion after successful coronary artery revasculazation.
Baer, et al.[ 6 5 ]w e r eo n eo ft h ef i r s ti n v e s t i g a t i v e
groups to report that implementation of low dose dobu-
tamine stress during CMR could be used to measure LV
myocardial thickening during low dose dobutamine. A
LV wall thickening response of < 1 mm denoted seg-
ments that lacked viability. They concluded that dobuta-
mine stress CMR results were better predictors of
residual metabolic activity as opposed to myocardial
SPECT imaging with a sensitivity of 81% versus 72%
and a specificity of 95% vs. 89%, respectively. In another
study from this same group, a CMR-derived systolic
wall thickening of ≥ 2 mm during low dose dobutamine
was found to predict LV segmental functional recovery
4-6 months after coronary arterial revascularization [66].
Similar results were reported by Sandstede, et al.[ 6 7 ] :
the sensitivity and specificity of low dose dobutamine
for the prediction of myocardial viability were 76% and
100%, respectively for patient-related analyses based on
coronary artery distribution.
Myocardial tissue tagging has been used as an adjunct
to dobutamine stress CMR to predict the viability of
hibernating or stunned myocardium. Geskin, et al. [68]
demonstrated that an improvement in contractility
within the midwall and subepicardium predicted future
functional recovery of the LV myocardium after coron-
ary arterial revascularization. Similar results have been
found by Bogaert, et al. [69] in studies of patients with
single vessel disease one week after successful reperfu-
sion of a first transmural anterior MI. Sayad, et al. [70]
found that the LV end systolic wall thickness measured
during low dose dobutamine infusion in patients with
chronic ischemic heart disease correlated with the LV
end systolic wall thickness 6 months after coronary
arterial revascularization.
Dendale and colleagues [71] evaluated the feasibility of
stress CMR use for the detection of viability after acute
MI. Gradient echo MR images were analyzed for WMA
during low doses of dobutamine in 37 patients sustain-
ing a recent MI. The authors concluded that low-dose
dobutamine MR imaging is a safe alternative to echocar-
diography to predict recovery of WMA after MI. In a
quantitative analysis, Saito and colleagues [72] compared
dobutamine stress CMR with DSE for identifying
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rest. The sensitivity of dobutamine stress CMR with tag-
ging was noted to be 76% whereas that of DSE was 66%.
The specificity of dobutamine stress CMR was 86% and
that of DSE was 100%. The accuracy of dobutamine
stress CMR was 78% while that of DSE was 72%.
In a recent study, Kramer, et al. [73] found that both
dobutamine stress CMR and DSE are sensitive and
accurate techniques for predicting functional improve-
ment after reperfused MI. In this study,
echocardiography was used as the reference for determi-
nation of functional recovery. Interestingly, the results
of MR tagging analyses demonstrated more segments
that would exhibit functional recovery at follow-up
when compared with echocardiography. They also
demonstrated that dobutamine stress CMR within 3
days of an acute MI was safe and well tolerated, even in
patients who underwent coronary artery stenting.
Another study by Zamorano, et al. [74] compared thal-
lium-201 redistribution imaging, cine dobutamine stress
Figure 6 Utility of Perfusion Testing During Dobutamine Stress: Top Left Image: Resting mid-left ventricular short axis with no
perfusion abnormalities. Top Right Image: Resting mid-left ventricular short axis slice after dobutamine stress demonstrating perfusion
abnormalities in the inferior (red arrow) and anterolateral (yellow arrow) regions. Bottom Left Image: Left anterior oblique view of the SVG to
distal RCA graft; red arrow points to a 70% lesion in the proximal body of the graft. Bottom Right Image: Right anterior oblique cranial view of
the left coronary system; red arrow points to diffuse disease in the mid-and distal left anterior descending artery; yellow arrow points to a 60%
lesion in the mid-circumflex coronary artery.
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Page 11 of 16CMR, and DSE for the assessment of myocardial viabi-
lity in 10 ischemic patients scheduled for heart trans-
plantation. The explanted hearts were analyzed to
quantify fibrosis using Mason trichrome staining. The
authors noted that the highest agreement was found
between DSE and CMR. In this study, perfusion imaging
by thallium-201 scintigraphy was found to be more sen-
sitive but less specific than assessment of contractile
reserve for the detection of myocardial viability.
A major strength of CMR in general relates to the
flexibility of the technology such that CMR functional
measures of contractile reserve can be acquired with
LGE (infarct detection) in a single comprehensive exam
(Figure 7). The complementary nature of these modal-
ities may lead to improved detection of myocardial via-
bility. As shown by Kramer, et al.[ 7 5 ]i nag r o u po f
patients with reperfused MI, using this combined tech-
nology, these investigators visualized infarcted or scarred
myocardium and simultaneously assessed contractile
reserve in residual myocardium.
In several other single-center studies, investigators have
performed dobutamine stress CMR both wall motion stu-
dies and late gadolinium enhancement imaging to predict
improvement of LV systolic function after coronary
arterial revascularization. These studies have been per-
formed in patients sustaining acute myocardial injury or
experiencing chronic ischemic heart disease [76-79].
Lauerma, et al., [76] and Wellnhoffer, et al., [77] identi-
fied that increased thickening during dobutamine stress
CMR was very useful for predicting functional recovery
of the LV myocardium in patients with an intermediate
amount of late gadolinium enhancement (1% to 49% of
Delayed Enhancement
End-systolic wall thickness stress
End-systolic wall thickness rest
Figure 7 Case example of contractile reserve supplementary delayed enhancement imaging for the purpose of identifying myocardial
viability. In the left panel, white arrows demarcate extensive delayed enhancement suggesting indicating marked fibrosis. The red arrow,
however, denotes a region with < 50% delayed enhancement. The red arrows in the right panels (top = rest and bottom = stress) demarcate no
improvement in end-systolic wall thickness with low-dose dobutamine stress. This finding suggests this segment will not improve wall
thickening after coronary arterial revascularization.
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ment). Bove, et al., [78] demonstrated that in segments
with 1 to 50% infarct transmurality, a normal dobutamine
response helped to differentiate segments with greater
functional recovery after revascularization. Motoyasu, et
al., [79] demonstrated similar results in 23 patients with
acute reperfused MI. Thus, in both acute and chronic
ischemic heart disease, it is those segments with inter-
mediate (≥ 1% but < 50%) transmural enhancement
where low dose dobutamine stress CMR results exhibit
additional clinical accuracy for predicting an ability of a
myocardial segment to recover function after coronary
arterial revascularization.
Some authors have suggested that combination of scar
determination and contractile reserve during dobutamine
administration improves the overall accuracy of CMR for
determining myocardial viability. Kaandorp, et al., [80]
tested this hypothesis in 48 patients with ischemic cardio-
myopathy and found that 61% of segments with an inter-
mediate extent of scar tissue on CMR had contractile
reserve and 39% lack contractile reserve. As new treatment
strategies develop for managing ischemic cardiomyopathy,
such as, stem cell placement, specialized left ventricular
assist device insertion, or multi-lead pacing systems, the
combination of tissue characterization and low dose func-
tional stimulation studies may provide the data necessary
to optimally deliver these specialized therapies. Since
CMR does not utilize ionizing radiation, it may become
one of the preferred testing modalities to longitudinally
gather this information in order to optimally direct deliv-
ery of these specialized therapies.
In addition to device related and other interventional
treatment strategies, low dose dobutamine CMR wall
motion responses may be able to guide medication
Sk
Family history of CAD
Obstructive Airways Disease
Smoker
Hypertension
Diabetes mellitus
279 patients
Undergoing 
Dobutamine CMR
Prior Q-wave Infarction
Prior Revascularization
Dobutamine CMR
Referred for 
assessment of
Obesity (BMI >27)
Hypercholesterolemia assessment of
chest pain
Followed 3 years
Age >65 years
Gender
Followed 3 years
Contractile reserve by MRI
LVEF <40% by MRI
10 1 0
Hazard ratio of MI or cardiac death
Figure 8 Multivariable analysis for contractile reserve predicting cardiac events. Hazard ratios ± 95% confidence intervals (x-axis) for
myocardial infarction or cardiac death in a multivariable (y-axis) analysis. As shown, contractile reserve is a predictor of adverse cardiac events
after accounting for risk factors for cardiac events.
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Page 13 of 16administration or forecast cardiac prognosis. A single
study has shown that an increase of LVEF during low-
dose dobutamine stress testing also predicts the
improvement of LV function after initiation of b-blocker
therapy [81].
Dobutamine assessments of contractile reserve appear
to predict cardiac events. In a study of Hundley, et al.,
subgroup analyses found the presence of contractile
reserve at low doses of dobutamine (7.5 to 10 mcg/kg/
min) in patients with coronary artery disease predicted
future MI and cardiac death after accounting for other
risk factors for cardiovascular events (Figure 8) [51].
Thus, in addition to selecting patients that would
improve LV performance after successful coronary
artery revascularization; low dose dobutamine CMR
results also forecast individuals at high risk for future
MI and cardiac death.
Summary
Dobutamine stress CMR is useful technique for identify-
ing myocardial ischemia and viability with high diagnos-
tic accuracy. This technique is of particular utility in
patients not well suited for other noninvasive imaging
techniques. Beside its diagnostic value, dobutamine
stress CMR results provide relevant prognostic informa-
tion regarding future risk of MI and cardiac death. Per-
formance of dobutamine stress CMR requires
appropriately trained staff, monitoring and safety mea-
sures. The combined assessment of wall motion, perfu-
sion and scar transmurality during single session CMR
imaging may prove to be imaging method of choice to
guide to the clinical management of patients with
known or suspected coronary artery disease.
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